Israeli drug development company BioLineRX has announced that it will receive an $8 million investment from OrbiMed Israel Partners LP. BioLineRX says that it will use the funds to continue the development of its clinical and pre-clinical state therapeutic assets.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Elbit Sells Air Defense System To Foreign Client For $50M
April 30, 2024
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Facebook comments